Search research articles
Contact Us
Filters
Showing results (31-40 of 35) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 35 results.
The New England Journal of Medicine
|
December 14, 2016
Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B
Divya Punwani, Yong Zhang, Jason Yu, et al.
The Journal of Allergy and Clinical Immunology
|
August 13, 2021
Poor T-cell receptor β repertoire diversity early posttransplant for severe combined immunodeficiency predicts failure of immune reconstitution
Ottavia M Delmonte, Riccardo Castagnoli, Jason Yu, et al.
Human Gene Therapy
|
September 10, 2016
Lentivirus Mediated Correction of Artemis-Deficient Severe Combined Immunodeficiency
Divya Punwani, Misako Kawahara, Jason Yu, et al.
Oncogene
|
October 14, 2022
AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors
Shanade Dunn, Cath Eberlein, Jason Yu, et al.
The New England Journal of Medicine
|
December 22, 2022
Lentiviral Gene Therapy for Artemis-Deficient SCID
Morton J Cowan, Jason Yu, Janelle Facchino, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 35) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 35 results.
The New England Journal of Medicine
|
December 14, 2016
Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B
Divya Punwani, Yong Zhang, Jason Yu, et al.
The Journal of Allergy and Clinical Immunology
|
August 13, 2021
Poor T-cell receptor β repertoire diversity early posttransplant for severe combined immunodeficiency predicts failure of immune reconstitution
Ottavia M Delmonte, Riccardo Castagnoli, Jason Yu, et al.
Human Gene Therapy
|
September 10, 2016
Lentivirus Mediated Correction of Artemis-Deficient Severe Combined Immunodeficiency
Divya Punwani, Misako Kawahara, Jason Yu, et al.
Oncogene
|
October 14, 2022
AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors
Shanade Dunn, Cath Eberlein, Jason Yu, et al.
The New England Journal of Medicine
|
December 22, 2022
Lentiviral Gene Therapy for Artemis-Deficient SCID
Morton J Cowan, Jason Yu, Janelle Facchino, et al.
Page
of 4